Phase 3 COPD Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 40 to 80 years old
- People who have been diagnosed with COPD for at least 1 year
- People whose lung function test results fall within a specific range at the screening visit (confirm with trial site for exact values)
- People who have been taking either triple inhaled COPD medication (a combination of ICS + LABA + LAMA) or dual inhaled COPD medication — if triple therapy was considered unsuitable — for at least 3 months in a row before the first visit
- People who have had at least 2 moderate COPD flare-ups, or at least 1 severe COPD flare-up, in the past year; at least one moderate flare-up must have been treated with steroid tablets or injections, and at least one flare-up must have occurred while the person was already on their inhaled COPD medications
- People whose blood test at screening shows a certain type of immune cell (eosinophils) at a level of 150 cells per microlitre or higher
- People whose COPD symptom score (measured by a questionnaire called the CAT) is 15 or higher at screening
- People who are current or former smokers with a smoking history of at least 10 pack-years (confirm with trial site for what this means in your situation)
Who may not be able to join:
- People who have another significant lung disease, or whose chest scans suggest a lung condition other than COPD
- People who have been diagnosed with asthma (including childhood asthma) or a combined asthma-COPD condition
- People who have any unstable health condition that could affect their safety or the trial results
- People who have needed treatment for tuberculosis within the 12 months before the second study visit
- People who currently have, or have previously had, cancer
- People who have been taking a type of antibiotic called macrolides for less than 6 months
- People who are taking medications that suppress or alter the immune system
- People who require long-term oxygen therapy at a flow rate above 4.0 litres per minute, or whose blood oxygen levels remain too low even while on long-term oxygen therapy
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Dave Singh, MD, Division of Infection, Immunity & Resp Medicine, The University of Manchester, United Kingdom
Phone: 1-877-240-9479
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Annualised rate of moderate or severe COPD exacerbations
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.